Completed PHASE2 INTERVENTIONAL 3-arm NCT00573781

Dietary Modulation of Gene Expression and Metabolic Pathways in Glucose Metabolism (Sysdimet)

Systems Biology Approach to Understand Dietary Modulation of Gene Expression and Metabolic Pathways in Subjects With Abnormal Glucose Metabolism (Sysdimet)

Sponsor: Marjukka Kolehmainen

Conditions Impaired Fasting Glucose Impaired Glucose Tolerance Metabolic Syndrome Obesity

Interventions Control diet with decreased intake of rye bread, berries and fish Diet with increased intake of rye bread, berries and fish Increased intake of whole grain and rye bread

Updated 5 times since 2017 Last updated: Apr 16, 2012 Started: Sep 30, 2007 Primary completion: Jun 30, 2009 Completion: Jun 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Impaired Fasting Glucose and Impaired Glucose Tolerance, this trial is completed. The trial is conducted by Marjukka Kolehmainen and has accumulated 5 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Marjukka Kolehmainen
VTT Technical Research Centre, Finland
Wageningen University

Data source: University of Eastern Finland

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kuopio, Finland